拉贝洛尔联合硫酸镁治疗妊娠期高血压的临床观察

Clinical Observation of Rabelor Combined with Magnesium Sulfate in the Treatment of Gestational Hypertension

目的探究拉贝洛尔联合硫酸镁治疗妊娠期高血压的临床效果。方法选取我院2018年4~12月收治的妊娠期高血压患者作为本次研究的实验对象,采用随机综合平衡法分为观察组(n=35)和对照组(n=35),对照组患者采用拉贝洛尔治疗,观察组采用拉贝洛尔联合硫酸镁治疗,对比两组治疗前后血压、24 h尿蛋白情况、母婴结局、不良反应发生率。结果两组治疗前血压、24 h尿蛋白对比无差异(P>0.05)。治疗后,观察组血压、24 h蛋白尿均低于对照组(P<0.05)。观察组患者产后出现出血、感染以及新生儿发生窒息、宫内窘迫的发生率低于对照组(P<0.05)。观察组药物不良反应发生率低于对照组(P<0.05)。结论妊娠期高血压患者采用拉贝洛尔联合硫酸镁治疗能有效降低血压和尿蛋白,减少了产妇产后以及新生儿相关并发症发生率,母婴结局良好,安全性高。

Objective To explore the clinical effect of rabelor combined with magnesium sulfate in the treatment of gestational hypertension.Methods From April 2018-December admitted during the period of gestation hypertension patients as the subjects of this study,using random comprehensive balance method is divided into observation group(n=35)and the control group(n=35),the control group were treated by labetalol treatment,observation group with labetalol joint magnesium sulfate treatment,compared two groups of 24 h urine protein,blood pressure before and after the treatment,and outcomes,the incidence of adverse reactions.Results Before treatment,there was no difference in blood pressure and 24 h urinary protein between the two groups(P>0.05).After treatment,blood pressure and 24 h proteinuria in the observation group were lower than those in the control group(P<0.05).The incidence of postpartum hemorrhage,infection,neonatal asphyxia and intrauterine distress in the observation group was lower than that in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Treatment with labelolol combined with magnesium sulfate can effectively reduce blood pressure and urinary protein in patients with gestational hypertension,reduce the incidence of postpartum and neonatal complications,and achieve a good maternal and infant outcome with high safety.